LONDON--(BUSINESS WIRE)--Technavio has been monitoring the regenerative medicine market and it is poised to grow by USD 9.55 billion during 2020-2024, progressing at a CAGR of over 20% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. are some of the major market participants. The increasing prevalence of chronic diseases will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Increasing prevalence of chronic diseases has been instrumental in driving the growth of the market.

Regenerative Medicine Market 2020-2024: Segmentation

Regenerative Medicine Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41171

Regenerative Medicine Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our regenerative medicine market report covers the following areas:

This study identifies the increasing number of clinical trials as one of the prime reasons driving the regenerative medicine market growth during the next few years.

Regenerative Medicine Market 2020-2024: Vendor Analysis

We provide a detailed analysis of vendors operating in the regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd., and Zimmer Biomet Holdings Inc. Backed with competitive intelligence and benchmarking, our research reports on the regenerative medicine market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Regenerative Medicine Market 2020-2024: Key Highlights

Table Of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Technology

Customer Landscape

Geographic Landscape

Drivers, Challenges, and Trends

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Originally posted here:
Research Report with COVID-19 Forecasts - Regenerative Medicine Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth |...

Recommendation and review posted by Bethany Smith

Facts & Factors Market Research, leading market research and consulting firm added the latest industry outlook report on Cancer Gene Therapy Market By Type (Ex-vivo and In-vivo) and By Product (Viral Vectors, Non-viral Vectors, and Others): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026 consisting of 190+ pages during the forecast period 2020 to 2026 and the Cancer Gene Therapy Market Market report offers comprehensive research updates and information related to market growth, demand, and opportunities in the Cancer Gene Therapy Market Market.

TheCancer Gene Therapy Market marketreport analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Cancer Gene Therapy Market market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Billion) from FY 2016 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Cancer Gene Therapy Market industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Request an Exclusive Free Sample Report of Cancer Gene Therapy Market Market:https://www.fnfresearch.com/sample/cancer-gene-therapy-market-by-type-ex-vivo-898

Our Every Readily Available Free Sample Includes:

Some of Top Market Players Analysis Included in this Report:

The Market Player Analysis based on some of below Factors:

Impact of COVID-19 Pandemic on Cancer Gene Therapy Market Market

The COVID-19 outbreak has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The decrease in the overall market growth due to COVID-19 is also affecting the growth of the Cancer Gene Therapy Market market owing to the shutting down of factories, obstacles in supply chain, and a downturn in the world economy.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Gene Therapy Market market by product type, application, key manufacturers and key regions and countries. In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Request Customized Copy of Report @https://www.fnfresearch.com/customization/cancer-gene-therapy-market-by-type-ex-vivo-898

(We customize your report according to your research need. Ask our sales team for report customization).

Available Customization Options:

The Cancer Gene Therapy Market Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

The report provides the complete view of the Cancer Gene Therapy Market market and encompasses a detailed type portfolio and strategic developments of key vendors. To know the competitive landscape of the Cancer Gene Therapy Market market, an analysis of Porters five forces model is done. The study cover market attractiveness analysis, in which type, source type, and application segments are specialized based on the market size, growth rate, and attractiveness.

The report study further includes an in-depth analysis of industry players market shares and provides an overview of leading players market position in the Cancer Gene Therapy Market sector. Key strategic developments in the Cancer Gene Therapy Market market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Cancer Gene Therapy Market market are appropriately highlighted in the report.

Make an Enquiry Before Purchase this Report @https://www.fnfresearch.com/inquiry/cancer-gene-therapy-market-by-type-ex-vivo-898

To Know More about Discount on Specific Report, Kindly Mail us at [[emailprotected]]with Your requirement. We will send you a quote and discount offer, if available.

KEY REPORT POINTERS & HIGHLIGHTS:

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +8621 80360450

E-Mail:[emailprotected]

Web:https://www.fnfresearch.com

Excerpt from:
Cancer Gene Therapy Market Size & Trends 2020 Research With COVID-19 Impact Analysis & Insights Report Forecast to 2026 - 3rd Watch News

Recommendation and review posted by Bethany Smith

SEATTLE, May 25, 2020 (GLOBE NEWSWIRE) -- Various lesions or diseases of the somatosensory system may lead to neuropathic pain. Nerve blockage and pharmacological remedies are used in the treatment and management of neuropathic pain.

The global neuropathic pain market is estimated to account for US$ 9,862.3 Mn in terms of value by the end of 2027.

Market Drivers:

High prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Market Opportunities:

R&D in neuropathic pain is expected to offer lucrative growth opportunities for players in the market. For instance, in May 2020, researchers from University Medical Center Hamburg-Eppendorf and other prominent universities in Germany reported that loss of C-fiber may lead to neuropathic pain in Schwannomatosis, a form of neurofibromatosis caused due to the occurrence of multiple schwannomas, tumors that develops from the Schwann cells.

Moreover, adoption of nanoparticles in therapies is also expected to aid in growth of the global neuropathic pain market. For instance, in May 2020, researchers from Chungnam National University Hospital, South Korea, reported that poly(D,L-lactic-co-glycolic acid)-encapsulated CX3CR1 small interfering RNAs nanoparticles may aid in the treatment of neuropathic pain.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/3656

Key Takeaways:

The global neuropathic pain market was valued at US$ 6,313.4 Mn in 2019 and is forecast to reach US$ 9,862.3 Mn by 2027 at a CAGR of 5.6% between 2020 and 2027. Increasing prevalence of cancer is expected to propel growth of the global neuropathic pain market over the forecast period.

Anticonvulsants segment held dominant position in the global neuropathic pain market in 2019, accounting for 40.8% share in terms of value. Development of new drugs for the treatment of neuropathic pain is expected to drive the segment growth.

Diabetic neuropathy segment held dominant position in the global neuropathic pain market in 2019, accounting for 46.4% share in terms of value, followed by Chemotherapy-induced peripheral neuropathy and others, respectively. Increasing prevalence of diabetic neuropathy in developing economies is expected to assist the growth of the segment during the forecast period.

Market Trends:

Various studies are focused on developing alternatives to drugs in the treatment of neuropathic pain. For instance, in March 2020, researchers at the Autonomous University of the State of Hidalgo, Mexico, reported that pomegranate and secondary metabolites can be effective in the treatment of inflammatory, nociceptive, and neuropathic pain.

The market is witnessing adoption of combination therapies as an effective approach in the treatment of neuropathic pain. For instance, in March 2020, researchers from Universitat Autnoma de Barcelona, Spain, reported that NeuroHeal a combination of two repurposed drugs: Acamprosate and Ribavirin reduces the appearance of neuropathic pain in peripheral nerve injury.

Competitive Landscape:

Major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., CODA Biotherapeutics, Inc., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, Neuroheal Biomedicals, S.L., and Depomed, Inc.

Key Developments:

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in May 2020, CODA Biotherapeutics, Inc. collaborated with the Facial Pain Research Foundation for R&D of new therapies for trigeminal neuralgia and related neuropathic pain using CODAs chemogenetic gene therapy platform.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3656

Taxonomy (Scope, segments)

Follow this link:
Neuropathic Pain Market to reach US$ 9,862.3 Million globally by 2027 Coherent Market Insights - GlobeNewswire

Recommendation and review posted by Bethany Smith

As the number of U.S. spinal muscular atrophy (SMA) patients Zolgensma treats each quarter stabilizes, Novartis is counting on a set of inflection points for future growth. Now, it has one.

After a manufacturing-related delay, Novartis has won conditional approval in the EU for the one-time gene therapy to treat patients with a clinical diagnosis of SMA type 1 and others with up to three copies of the SMN2 backup gene, the company said Monday.

Zolgensmas EU label is different from the U.S. version. While its approved by the FDA to treat children less than 2 years of age, the EMA allows it in babies and young children who weigh up to 21 kilograms. According to a Pediatric Neuromuscular Clinical Research natural history study of SMA, almost all patients under the age of 5 will be under 21 kg.

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

The number of SMN2 genes determines the severity of the disease, with SMA type 1 the most severe form. The U.S. approval is for all SMA types, but the EU nod leaves out a small proportion of patients who could develop mild, late-onset type 3 or type 4 SMA. Patients with type 3 SMA, sometimes called Kugelberg-Welander disease, may have up to four copies of SMN2.

The difference could havemixed effectson Zolgensmas opportunity in the two territories. For existing patients already on Biogens Spinraza, Zolgensma could steal share from older patients in the EU. But for new patients, the FDA label enables the Novartis drug to reach more patients if diagnosis through newborn screening is widely adopted and patients are treated early.

Zolgensma has reached a steady state where it treats about 100 patients per quarter in the U.S., Novartis CEO Vas Narasimhan recently told investors. That translated into $170 million sales in the first quarter, a slight quarter-over-quarterdecline due to COVID-19. The companys expecting approvals in new countriesand new indications to be inflection points that will eventually propel the drug to blockbuster sales.

RELATED:The top 10 drug launches since 2017 | 7. Zolgensma

It had the first point in March with a Japanese nod, also for patients under 2 years old. Last week, the Japanese government approved Zolgensmas price at 167 million yen ($1.55 million), lower than its U.S. list price of $2.12 million.

In Europe, final pricing and reimbursement decisions will be determined at the local level, a spokesperson at Novartis AveXis gene therapy unit told FiercePharma. Cumulative healthcare costs per SMA patient are estimated at between 2.5 million to 4 million over the first 10 years, the company said.

Novartis said its working with European countries local regulators on an access program called Day One. Its designed to provide fast access to Zolgensma even before national pricing and reimbursement agreements are in place, a process that sometimes takes years. The program offers several options such as deferred payments and installment over years as well as outcomes-based rebates. The drug has been made available in France under the countrys Temporary Authorization for Use pathway, and access is expected shortly in Germany, the Swiss drugmaker said.

Beyond the already-approved intravenous version, Novartis is developing a formulation that delivers Zolgensma through an injection into the spinal canal so that it can reach older patients up to 5 years of age in the U.S. Its working with the FDA to resolve a partial clinical hold slapped on the high dose of the intrathecal formulation before it can file for an approval.

Currently, AveXis makes Zolgensma at its site in Libertyville, Illinois. It also has plants in Durham, North Carolina, and Longmont, Colorado. The latter two are expected to be licensed in 2021, the company spokesperson said, adding that it has no plans for a manufacturing facility in the EU at this point.

Read the rest here:
New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy - FiercePharma

Recommendation and review posted by Bethany Smith

COVID-19 Impact Analysis of Hemophilia Gene Therapy Market

[Los Angeles], [United States], May 2020, The Hemophilia Gene Therapy Market research report includes an in-sight study of the key [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026] market prominent players along with the company profiles and planning adopted by them. This helps the buyer of the Hemophilia Gene Therapy report to gain a clear view of the competitive landscape and accordingly plan Hemophilia Gene Therapy market strategies. An isolated section with top key players is provided in the report, which provides a complete analysis of price, gross, revenue(Mn), Hemophilia Gene Therapy specifications, and company profiles. The Hemophilia Gene Therapy study is segmented by Module Type, Test Type, And Region.

The market size section gives the Hemophilia Gene Therapy market revenue, covering both the historic growth of the market and the forecasting of the future. Moreover, the report covers a host of company profiles, who are making a mark in the industry or have the potential to do so. The profiling of the players includes their market size, key product launches, information regarding the strategies they employ, and others. The report identifies the total market sales generated by a particular firm over a period of time. Industry experts calculate share by taking into account the product sales over a period and then dividing it by the overall sales of the Hemophilia Gene Therapy industry over a defined period.

Download Full PDF Sample Copy of Report: https://www.qyresearch.com/sample-form/form/1436276/global-hemophilia-gene-therapy-market

Key Manufacturers of Hemophilia Gene Therapy Market include: Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics

The research covers the current market size of the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026]and its growth rates based on 5 year history data. It also covers various types of segmentation such as by geography North America, Europe, Asia-Pacific etc., by product type Hemophilia A, Hemophilia B, by applications Hemophilia A Gene Therapy, Hemophilia B Gene Therapy in overall market. The in-depth information by segments of Hemophilia Gene Therapymarket helps monitor performance & make critical decisions for growth and profitability. It provides information on trends and developments, focuses on markets and materials, capacities, technologies, CAPEX cycle and the changing structure of the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026].

This study also contains company profiling, product picture and specifications, sales, market share and contact information of various international, regional, and local vendors of [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026]. The market competition is constantly growing higher with the rise in technological innovation and M&A activities in the industry. Moreover, many local and regional vendors are offering specific application products for varied end-users. The new vendor entrants in the market are finding it hard to compete with the international vendors based on quality, reliability, and innovations in technology.

Read Detailed Index of full Research Study: https://www.qyresearch.com/index/detail/1436276/global-hemophilia-gene-therapy-market

Geographically,this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Hemophilia Gene Therapyin these regions, from 2012 to 2022 (forecast), covering

Please Check below Chapters to display the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026].

There are 15 Chapters to display the [Global Hemophilia Gene Therapy Market Size, Status and Forecast 2020-2026].

Chapter 1, to describe Definition, Specifications and Classification of Hemophilia Gene Therapy, Applications of Hemophilia Gene Therapy, Market Segment by Regions;

Chapter 2, To analyse the Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;

Chapter 3, to display the Technical Data and Manufacturing Plants Analysis of Hemophilia Gene Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;

Chapter 4, to show the Overall Market Analysis, Capacity Analysis (Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics), Sales Analysis (Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics), Sales Price Analysis (Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics);

Chapter 5 and 6, to show the Regional Market Analysis that includes North America, Europe, Asia-Pacific etc., Hemophilia Gene Therapy Segment Market Analysis (Hemophilia A, Hemophilia B);

Chapter 7 and 8, to analyse the Hemophilia Gene Therapy Segment Market Analysis (Hemophilia A Gene Therapy, Hemophilia B Gene Therapy) Major Manufacturers Analysis of Hemophilia Gene Therapy;

Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type [Type], Market Trend [Hemophilia A Gene Therapy, Hemophilia B Gene Therapy];

Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;

Chapter 11, to analyse the Consumers Analysis of Hemophilia Gene Therapy;

Chapter 12, to describe Hemophilia Gene Therapy Research Findings and Conclusion, Appendix, methodology and data source;

Chapter 13, 14 and 15, to describe Hemophilia Gene Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

See the rest here:
Global Hemophilia Gene Therapy Market 2020 Business Outlook with COVID-19 Scenario Analysis and Forecast 2026 - Weekly Wall

Recommendation and review posted by Bethany Smith

Global Cancer Gene Therapy market report studies the market situation and outlook represents the global Cancer Gene Therapy market size (value and volume) and Share by companies, type, application, and region. The widespread Global Cancer Gene Therapy trends and opportunities are also taken into consideration in Cancer Gene Therapy industry study Cancer Gene Therapy Market report focus on the following section is to analyze the Cancer Gene Therapy industry by adoption among various segments; the primary product types covered under the scope of the report.

This Cancer Gene Therapy market report is a complete analysis of the Cancer Gene Therapy market based on primary and secondary in-depth analysis. The scope of the Cancer Gene Therapy market report includes global and regional sales, product consumption in terms of volume, and value. The global Cancer Gene Therapy market report provides an estimate of revenue, CAGR, and aggregate revenue. The collected knowledge about Cancer Gene Therapy global business is represented in the figures, tables, pie charts, and graphs.

Get FREE Research Sample By Using Corporate Mail ID @https://market.us/report/cancer-gene-therapy-market/request-sample

MANUFACTURERScovered in this Cancer Gene Therapy market report:

Sun-Maid, Arimex, Olam International, Sunbeam Foods, Diamond Foods, Archer Daniels Midland, Kanegrade, Graceland, Hines Nut Company, H.B.S. Foods

On the basis of product each TYPES primarily split into:

Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

On the basis of product each APPLICATIONS primarily split into:

Hospitals, Diagnostics Centers, Research Institutes

Market Primarily Focusing On Cancer Gene Therapy Market:

South America & including countries

The Middle East and Africa

North America

Europe

Asia-Pacific & included countries.

Customized Research ReportUsing Corporate Email Id @ https://market.us/report/cancer-gene-therapy-market/#inquiry

Global Cancer Gene Therapy Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global Cancer Gene Therapy market and also about each type from 2015 to 2029. This section mentions the volume of sales by region from 2015 to 2029. Pricing analysis is included in the report according to each type from the year 2015 to 2029, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2029.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing Cancer Gene Therapy market. Additionally, insights into market experts opinions have been taken to understand the market better.

Global Cancer Gene Therapy Market: Segment Analysis

The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2029. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the Cancer Gene Therapy market growth.

Global Cancer Gene Therapy Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Cancer Gene Therapy report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2029. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Cancer Gene Therapy Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the Cancer Gene Therapy market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

PurchaseWhole Research Analysis @ https://market.us/purchase-report/?report_id=54259

CONTACT US :

Mr. Benni JohnsonMarket.us (Powered By Prudour Pvt. Ltd.)

Email:[emailprotected]

Address:

420 Lexington Avenue,Suite 300 New York City,NY 10170, United StatesTel: +1 718 618 4351

Website:https://market.us

More RelatedReports Here:

Expanded Polytetrafluoroethylene Market with Pertinent Opportunities by 2029 | GORE and Guarnitex

World News For Active Pharmaceutical Ingredients Market | Increased Research and Development Activities Boosts by 2020-2029 | BioSpace

Specific Equipment Reports @https://chemicalmarketreports.com/

See the original post:
Impact of COVID-19 on Global Cancer Gene Therapy Market Research Segment (2020-2029) || Sun-Maid, Arimex, Olam International - Cole of Duty

Recommendation and review posted by Bethany Smith

XconomyNational

COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list of life science companies preparing to join the public markets.

Gene therapy company Generation Bio, vaccines developer Vaxcyte, and cancer diagnostics maker Burning Rock Biotech each filed IPO paperwork just ahead of the Memorial Day weekend. The filings come as an index of the largest and most liquid IPOs of the past two years reached an all-time high, according to Renaissance Capital. The IPO research firm says the indexs rise was led by Moderna (NASDAQ: MRNA), the Cambridge, MA-based biotech that this week released preliminary Phase 1 data for its experimental COVID-19 vaccine.

Investors are betting that new technologies and services are best suited for the post-pandemic world, Renaissance says.

Heres a look at the three new additions to the biotech IPO queue.

GENERATION BIO EYES NEXT-GEN GENE THERAPIES

Generation Bio aims to improve upon gene therapy with an alternative to the engineered viruses currently used to ferry these therapies into cells. Viral delivery has limitations that include safety risks and a relatively small genetic payload capacity, the Cambridge-based company says in its filing. Furthermore, if patients dont already have antibodies to the viruses, they develop them after their first dose, which means patients cant receive additional doses if the initial one doesnt work as expected or stops working over time. Gene therapies that employ viral delivery are also expensive to manufacture.

Instead of a virus as its delivery vehicle, Generation Bio uses a lipid nanoparticle (LNP). The LNP encapsulates its genetic payload, a DNA construct called closed-ended DNA. This approach permits an individualized approach to treatment as a patient can be redosed until reaching the level needed for effective treatment, the company says. The technology also has a greater payload capacity and its less expensive to manufacture at scale compared to viral gene therapies. Those differences will enable delivery of gene therapies to more types of tissue, which in turn will allow for the treatment of a broader range of diseases spanning more patients, Generation Bio says.

Generation Bios initial focus is developing gene therapies targeting diseases of the liver and the eye. The most advanced liver programs are for phenylketonuria (PKU), an inherited metabolic disorder, and hemophilia type A, the most common form of the bleeding disorder. For the eye, Generation Bio is developing a gene therapy for an inherited form of vision loss called Leber congenital amaurosis 10 (LCA10) and for Stargardt disease, which is a form of macular degeneration.

Those programs trail other experimental gene therapies that are currently in clinical testing. Pfizer (NYSE: PFE) is developing a hemophila A gene therapy that came from the labs of partner Sangamo Therapeutics (NASDAQ: SGMO). BioMarin Pharmaceutical (NASDASQ: BMRN) is testing gene therapies for hemophilia A and PKU. In LCA10,Editas Medicine (NASDAQ: EDIT) is developing a gene therapy under a partnership with Allergan, now a subsidiary of AbbVie (NYSE: ABBV). That therapeutic candidate uses the CRISPR gene-editing technology to correct the faulty gene inside the patient. All of these experimental gene therapies use adeno-associated viruses to reach their targets.

Generation Bio has raised more than $227 million, most recently a $110 million Series C financing in January. That funding round added crossover investors, whose involvement is viewed as an indication a company is preparing for an IPO. CEO Geoff McDonough acknowledged as much at the time, telling Xconomy he expected to take the company public in advance of beginning clinical trials. Other rare diseases that the company is exploring include Wilsons disease and Gaucher disease.

In its filing, Generation Bio set a preliminary $125 million target for its IPO. The company has applied for a Nasdaq listing under the stock symbol GBIO. At the end of the first quarter of this year, Generation Bio reported having $104.5 million in cash. The company says it plans to use the IPO proceeds to continue R&D, including the preclinical work to support an application to start clinical testing of one of its liver disease gene therapies.

Generation Bios largest shareholders are Jason Rhodes, the companys chairman and founding CEO, and Atlas Venture. Each holds a 37 percent pre-IPO stake, according to the filing. Fidelity Investment owns 14.9 percent of the company, followed by funds advised by T. Rowe Price, which hold 8.9 percent.

VAXCYTE SETS SIGHTS ON TOPPING A PFIZER VACCINE

Vaxcyte is the new name for SutroVax, which changed its moniker this week. The Foster City, CA-based company spun out of Sutro Biopharma, and it develops vaccines using technology licensed from its former parent. The company says in its IPO filing that its cell-free protein synthesis technology enables it to design protein carriers and antigensa vaccines key componentsthat are better than what can be produced using conventional vaccine technologies.

Pneumococcal bacteria, which can cause pneumonia and meningitis, are Vaxcytes first target. The top pneumococcal vaccine, a Pfizer (NYSE: PFE) product called Prevnar 13, is a blockbuster seller that protects against 13 of the more than 90 pneumococcal strains. Vaxcytes preclinical vaccine candidate, VAX-24, is being developed to address 24 strains.

The IPO filing comes two months after Vaxyte closed a $110 million Series D round that added crossover investors. The company says in the filing that it has raised about $282 million cumulatively. As of March 31, Vaxcytes cash holdings totaled $154.7 million. The companys largest shareholders include Abingworth Bioventures, Longitude Capial Management, and Roche Finance, though the percentages of those stakes were not disclosed.

Vaxcyte says it plans to apply for a Nasdaq listing under the stock symbol PCVX. The vaccine developer set a preliminary $100 million goal; proceeds will be used to complete preclinical development and advance VAX-24 into human testing. The cash will also finance manufacturing, as well as continued development of other vaccine candidates.

BURNING ROCK BIOTECH BLAZES A PATH TO NASDAQ

Burning Rock Biotech is based in China, where it sells next-generation sequencing products that help physicians select cancer treatments for their patients. Now its seeking a Nasdaq listing that will give US investors a chance to grab a stake.

The company says in its filing that it offers 13 tests spanning solid tumors including cancers of the lung, prostate, and breast, as well as blood cancers. In addition helping physicians treat cancer patients, Burning Rock says its products support clinical trials conducted by large pharmaceutical companies, including AstraZeneca (NYSE: AZN), Bayer, and Johnson & Johnson (NYSE: JNJ). The companys central laboratory processes biopsy samples from hospital patients as well as from its pharmaceutical partners. The central lab business is the companys largest business segment.

Burning Rock reported $53.9 million in 2019 revenue. For the first quarter of 2020, revenue was $9.5 million. The company set a preliminary $100 million goal for its IPO, and says it plans to apply for a Nasdaq listing under the stock symbol BNR. According to the filing, Burning Rock expects to use the IPO cash for research and development of early cancer detection technologies, as well as for seeking approvals in China for additional cancer therapy selection products.

Image: iStock/peterschreiber.media

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan@xconomy.com.

Originally posted here:
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq - Xconomy

Recommendation and review posted by Bethany Smith

Others at the center, which coordinates research at eight universities, are reviewing past work on drugs that showed potential against the SARS epidemic in 2002 and the MERS outbreak in 2012. Both diseases are also caused by coronaviruses.

At some point, though, scientists at the center and across the country will need to focus on future threats and break new ground.

You can make a lot of movement fast, based on what you know, Satchell said. But at some point, you hit a wall where you have to discover new things.

Andy Mesecar needs a weekend off.

An expert in biochemistry and gene therapy, hes worked seven-day weeks for the last few months, racing to find a drug for patients with COVID-19 while teaching at Purdue University and submitting daily reports to the National Institutes of Health. The center at Northwestern has funded his work since 2018.

Mesecar has a manuscript under review in a scientific journal on how a drug approved to treat hepatitis C could be modified to potentially treat COVID-19. His lab is one of the leading centers studying coronaviruses, and he and his team have dedicated nearly two decades to the research. But that was still not enough to rapidly create an effective therapy specific to COVID-19.

With a background in biochemistry and structural biology, Mesecar started out as an assistant professor at the University of Chicago, studying enzymes that could fight cancer. He got into infectious diseases after the anthrax attacks in the weeks after 9/11. Then, he pivoted to studying enzymes that could be used against SARS when it surfaced in November 2002.

Originally posted here:
Everything we did was to predict the next outbreak. Yet scientists werent prepared for COVID-19. Why? - Longview Daily News

Recommendation and review posted by Bethany Smith

Stem Cell Manufacturing Marketis expected to reach USD 16.51 Billion by 2025, from USD 10.28 Billion in 2017 growing at a CAGR of 6.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Get Sample Report PDF | @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-artificial-intelligence-market

The Global Stem Cell Manufacturing Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of stem cell manufacturing market for global, Europe, North America, Asia Pacific and South America.

Major Market competitors/players: Global Stem Cell Manufacturing Market

Some of the major players operating in the stem cell manufacturing market are Thermo Fisher Scientific. Merck Group, Becton, Dickinson and Company. Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis Inc, Osiris Therapeutics, Osiris Therapeutics, Vericel Corporation, AbbVie, American CryoStem, AM-Pharma, Anterogen.Co.,Ltd, Astellas Pharma, Bristol-Myers Squibb, Apceth Biopharma, Cellular Dynamics International, Rheacell, Takeda Pharmaceutical, Teva Pharmaceutical Industries Ltd. ViaCyte, VistaGen Therapeutics Inc, Translational Biosciences, GlaxoSmithKline plc, Daiichi Sankyo Company, Limited, among others.

Global Stem Cell manufacturing Market,By Application (Research Applicationsand Clinical Applicationsand Cell and Tissue Banking), By Product (Stem Cell Line, Instruments, Culture Media and Consumables), By End Users (Hospitals and Surgical Centers, Pharmaceutical and Biotechnology Companies, Clinics, Community Healthcare, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Table of Contents:

Highlights of the Study

Inquire about this report from our experts @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-manufacturing-market

Major Market Drivers:

Report Scope

Our purpose is to serve you, the most customised in-depth Market access data. Our plethora of titles, made us one of the most searched market research library across the globe. We work with the most esteemed Publishers around the globe who caters vast industries. We are quick and fragile, when it comes to your various queries, and we ensure our team cater your needs to the best of our abilities, we promise to stay by your side for both pre and post sales servicing, as we believe in long everlasting symbiotic relationship.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:[emailprotected]

View post:
COVID-19 UPDATE : STEM CELL MANUFACTURING MARKET 2020 FUTURE GROWTH WITH TOP PLAYERS THERMO FISHER SCIENTIFIC. MERCK GROUP, BECTON, DICKINSON AND...

Recommendation and review posted by Bethany Smith

Latest Market Research Report onGene Therapies for Cancer Treatment Market size | Industry Segment by Applications (Cancer Research Centers, Diagnostic Laboratories, Cancer Hospitals and Others), by Type (Somatic Cell Gene Therapy (SCGT) and Germline Gene Therapy (GGT), Regional Outlook, Market Demand, Latest Trends, Gene Therapies for Cancer Treatment Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

Gene Therapies for Cancer Treatment Market Report encompasses market attributes, size, growth forecast, segmentation, regional classifications, competitive landscape, Gene Therapies for Cancer Treatment market shares, trends and tactics of Gene Therapies for Cancer Treatment market. Gene Therapies for Cancer Treatment Marketreport highlights key dynamics of Global Gene Therapies for Cancer TreatmentIndustry sector. The potential of the Gene Therapies for Cancer TreatmentMarket has been investigated along with the key challenges. The current Gene Therapies for Cancer TreatmentMarket scenario and prospects of the sector has also been studied.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/18524

As per the report, the Gene Therapies for Cancer Treatment market has been further divided into crucial segments. A brief of the industry with regards to the market size in terms of the volume and renumeration aspects, as well as the current picture of Gene Therapies for Cancer Treatment market has been included in the report. The research speaks about the information related to the geographical segment of this vertical along with the firms that have achieved a significant position across the marketplace.

Gene Therapies for Cancer Treatment Market Report covers themanufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc.,these data help the consumer know about the competitors better. This report also covers all theregions and countries of the world, which shows a regional development status, includingGene Therapies for Cancer Treatment market size, volume and value, as well as price data.

Report Scope:

Gene Therapies for Cancer Treatment market competition by top Manufacturers:

Gene Therapies for Cancer Treatment Market Outlook by Applications:

Gene Therapies for Cancer Treatment Market Statistics by Types:

An Outline of Gene Therapies for Cancer Treatment Market report covers:

This report for Gene Therapies for Cancer Treatment Market discovers diverse topics such as regional market scope, product market various applications, market size according to specific product, sales and revenue by region, manufacturing cost analysis, Industrial Chain, Market Effect Factors Analysis, market size forecast, and more.

A vital point from TOC of Gene Therapies for Cancer Treatment Market analysis report are as below:

Executive Summary

Market Drivers, Challenges and Trends

Marketing, Distributors and Customer

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/18524

See the rest here:
Gene Therapies for Cancer Treatment Industry Size 2019, Market Opportunities, Share Analysis up to 2025 - ZZReport

Recommendation and review posted by Bethany Smith

The global Gene Therapy market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Gene Therapy market player in a comprehensive way. Further, the Gene Therapy market report emphasizes the adoption pattern of the Gene Therapy across various industries.

The Gene Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Gene Therapy market provides a birds eye view of the current proceeding within the Gene Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Gene Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2654974&source=atm

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Gene Therapy market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Gene Therapy market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Therapy market.The following players are covered in this report:Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.AdvantageneGene Therapy Breakdown Data by TypeEx vivoIn VivoGene Therapy Breakdown Data by ApplicationCancerMonogenicInfectious diseaseCardiovascular diseaseOther

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2654974&source=atm

The Gene Therapy market report offers a plethora of insights which include:

The Gene Therapy market report answers important questions which include:

The Gene Therapy market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2654974&licType=S&source=atm

Why Choose Gene Therapy Market Report?

Gene Therapy Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Continue reading here:
Coronavirus threat to global Gene Therapy Market Size, Demand, Cost Structures, Latest trends, and Forecasts to 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

(MENAFN - iCrowdNewsWire) May 25, 2020

The hemophilia treatment market was valued at US$ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US$44,089.71 million by 2027.

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

Get sample PDF Report @ https://www.theinsightpartners.com/sample/TIPRE00008241/

Some of the prominent players operating in hemophilia treatment market are, Bayer AG, Sanofi, F. Hoffmann-la Roche Ltd., Kedrion S.P.A., CSL Limited, Biotest AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, and Baxter International Inc. The market players are focused towards acquisitions with industry players in order to sustain their position in the market. For instance, in February 2020, Novo Nordisk launched an antihemophilic product namely Esperoct. This product is likely to reduce the effect of hemophilia in adults and children with hemophilia A.

The hemophilia treatment market by product is segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents, desmopressin. In 2019, the plasma derived coagulation factor concentrates segment held a largest market share of the hemophilia treatment market. This segment is also expected to dominate the market in 2027. The large share of plasma derived coagulation factor concentrates based hemophilia treatment can be attributed to various advantages offered by these hemophilia treatment, deep market penetration and variety of products offered by multiple players to suit diverse medical application. On the other hand, the recombinant coagulation factor concentrates segment is anticipated to witness the highest growth rate during the forecast period. Certain factors such as effectiveness of the hemophilia treatment in lesser time and better efficient blood clotting are expected to drive the segment growth.

The plasma derived coagulation factor concentrates based hemophilia treatment captured the largest share in the globalhemophilia treatment market. A wide variety of hemophilia treatment is available as adjunctive measures to improve hemophilia if residual bleeding persists despite the correct application of conventional methods for hemorrhage control. Plasma-derived coagulation factor hemophilia treatment is considered to be active agents that participate in the coagulation cascade to form fibrin clots and are effective to make an intact coagulation system. Plasma is the liquid part of blood. It is pale yellow or straw-colored with proteins such as antibodies, albumin, and coagulation factors. There are several target factor drug products made from plasma proteins of human. The plasma is collected from group of people, and perform several processes to separate the plasma into its components.

In Italy, according to the data of the National Center for Biotechnology Information (NCBI) in 2017, the number of registered people with bleeding disorders increased from about 7000 in 2000 to around 8500 in 2011 and more than 11,000 in 2015. The trend is due to an upsurge in the number of patients who are recorded, mainly in those with vWD type 1, mild hemophilia, or other factor deficiencies.

Inquiry For Discount @ https://www.theinsightpartners.com/discount/TIPRE00008241/

The report segments the global hemophilia treatment market as follows:

Global Hemophilia Treatment Market By Product

Global Hemophilia Treatment Market By Disease

Global Hemophilia Treatment Market By Treatment Type

Global Hemophilia Treatment Market By Therapy

Global Hemophilia Treatment Market By End User

Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00008241/

About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

MENAFN2505202000703403ID1100221306

Original post:
Hemophilia Treatment Market Analysis, By Key Players, Sale, Trends, Segmentation And Forecast By 2027 - MENAFN.COM

Recommendation and review posted by Bethany Smith

Fact.MR recently published a market study on Gene Therapy. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities & restraints, and detailed information about the Gene Therapy market structure. The market study suggests that the global market size of Gene Therapy is projected to reach a CAGR of xx% over the stipulated timeframe2020-2026.

Key indicators of market growth, which include year-on-year (Y-o-Y) growth of the market, value chain, supply chain analysis, and compounded annual growth rate (CAGR) are explained in Fact.MRs study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the Gene Therapy market during the forecast period.

Request for Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The study is relevant for stakeholders in the Gene Therapy market, including Gene Therapy manufacturers, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the Gene Therapy market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in Fact.MRs study.

To know How COVID-19 Pandemic Will Impact This Market/Industry | Request a sample copy of the This Market report:

The study also includes statistics as well as facts related to the macro as well as microeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the Gene Therapy market. Furthermore, small businesses and new entrants in the Gene Therapy market too can make use of the information presented in this study, based on which, they can make appropriate business decisions in order to gain momentum in the market.

Important regions covered in the Gene Therapy market report include:

The Gene Therapy market report highlights players below:

The global Gene Therapy market report also covers consumption and production of products. The types are as follows:

On the basis of end-use, the report includes:

Key Questions Answered in Fact. MRs Gene Therapy Market Report

Gene Therapy Market: Research Methodology

In Fact.MRs study, a unique research methodology is utilized to conduct extensive research on the growth of the Gene Therapy market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the Gene Therapy market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Send an Enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

Comprehensive information acquired from primary resources and secondary resources acts as a validation from companies in the soy protein concentrate market, and makes Fact. MRs projection on the growth prospects of the Gene Therapy market more accurate and reliable.

Choosing Fact.MR Reasons to Stay Ahead of the Curve

Continued here:
COVID-19 Industry Impact: Gene Therapy Analyzed for Forecast Year - The Cloud Tribune

Recommendation and review posted by Bethany Smith

Global Neurologic Disorders Therapeutics Market: Overview

In todays age, neurologic disorders are becoming increasingly common, especially neurodegenerative diseases. According to various studies, the growth of these neurological disorders is spreading rapidly across Europe and other parts of the world. In addition to this, the treatment for such disorders is also very challenging because of the presence of the strictly regulated blood-brain barrier. It is also challenging due to the unique ability to cover the brain from the new therapeutics. Traditional therapeutics, although effective, are still below the optimum level required for efficient treatment. Hence, there is need for finding newer and more effective therapeutics. This has thus given rise to the neurologic disorders therapeutics market.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6000

Global Neurologic Disorders Therapeutics Market: Notable Developments

Some of the notable developments in the global neurologic disorders therapeutics market are listed below:

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6000

Names of other notable players in the global neurologic disorders therapeuticsmarket are listed below:

Global Neurologic Disorders Therapeutics Market: Drivers and Restraints

There are several factors that are influencing the growth of the global neurologic disorders therapeutics market. One of the key driving factors is the increasing advances in the diagnosis of the different neurodegenerative indications. This has helped in increasing the demand for new therapeutics to effectively treat such neurodegenerative disorders. The early determination such disorders is difficult due to its complex nature of such disorders, lack of efficient diagnostics, and its fast progression. This has naturally helped in driving the activities of research and development for more effective treatment. Governments across the globe are also helping research institutes by allotting more funds for the development of new neurologic disorder therapeutics.

Global Neurologic Disorders Therapeutics Market: Geographical Outlook

The global neurologic disorders therapeutics market is primarily divided into five key regions viz. North America, Latin America, the Middle East and Africa, Europe, and Asia Pacific. Of these, the global neurologic disorders therapeutics market is primarily dominated by North America region. This is because of the high aging population in the region, advancements in technology, and highly developed healthcare infrastructure.

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6000

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Original post:
Neurologic Disorders Therapeutics Market Scope and Opportunities Analysis 2018 2028 - Cole of Duty

Recommendation and review posted by Bethany Smith

The Expression Vectors market report on the world market encompasses an evaluation of distinct parameters that uplift the growth of the global industry. In addition to this, all the industry manufacturers can utilize the market report to create themselves for facing tough market challenges and further competition in the universal market. Insightful information on notable strategies adopted by vital firms along with their key impact on the industry growth has been administrated in this market document. This Expression Vectors market research report gives explanation of market restraints, key drivers, and industry trends that transform the international market either in a positive or negative manner.

Get ExclusiveSample Copy of This Report Herehttps://www.databridgemarketresearch.com/request-a-sample?dbmr=global-expression-vectors-market

Market AnalysisBesides target market information, DBMR also provides information about your competitor, your customers, products etc. A few techniques we use are: Customer analysis Competitor analysis Risk analysis Product research Advertising research E-mail survey and many more

Globalexpression vectorsmarketis set to witness a substantial CAGR of 6.3% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. The rise in the market value can be attributed to increasing prevalence of infectious diseases, genetic disorders and other lifestyle associated diseases.

Some of the major players operating in globalexpression vectors marketareDNA TwoPointO Inc., Thermo Fisher Scientific, Inc., Promega Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories Inc., QIAGEN, Merck KGaA, TAKARA HOLDINGS Inc., New England Biolabs, GenScript, Quest Diagnostics ,Synbio Technologies, Addgene,Inc., BD, OriGene Technologies, Inc., InvivoGen, GeneCopoeia, Inc., ATCC, tebu-bio, System Biosciences, LLC., Sanofi, transOMIC, Genlantis Inc., Macrogen, Inc. and Gene Bridges GmbH among others.

Read Complete Details with TOC Herehttps://www.databridgemarketresearch.com/toc?dbmr=global-expression-vectors-market

Market Definition: Global Expression VectorsMarket

Expression vector is a vector that is used in genetic engineering which enables a particular gene to be cloned and expressed in a host cell.These vectors are also used in genetics, molecular biology and computer sciences. A specific gene is initiated to enter into a target cell via expression vector. Protein expression is a technique in which proteins are modulated, transformed and synthesized in living organisms or cells.

In2019, the statistics obtained from the American Cancer Societys publication and the National Cancer Institutes Surveillance Epidemiology, is believed that 268,600 women and 2,670 men in the United States will be diagnosed with breast cancer. It is estimated that from breast cancer 42,260 deaths will occur this year.Wide variety of cancers can be treated by multiple gene therapy strategies, including suicide gene therapy and therapeutic gene vaccines.

Segmentation:Global Expression VectorsMarket

Expression Vectors Market : By Host Type

Expression Vectors Market : By Application

Expression Vectors Market : By End User

Expression Vectors Market : ByGeography

Key Developments in the Expression Vectors Market :

Expression Vectors Market : Competitive Analysis:

Globalexpression vectorsmarketis highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares ofexpression vectorsfor Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence and Regulatory Affairs Managers among others.

Opportunities in the Expression Vectors Market Report :

Want Full Report? Enquire Herehttps://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-expression-vectors-market

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:[emailprotected]

Read the original here:
Covid-19 Impact On Global Expression Vectors Market 2020 : Industry Trends, Size, Growth, Swot Analysis By Top Key Players And Forecast Report To 2026...

Recommendation and review posted by Bethany Smith

The market research report published by QYResearch is a brilliant, in-dept, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Global Advanced Therapy Medicinal Products market. It informs readers about key trends and opportunities in the global Global Advanced Therapy Medicinal Products market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Global Advanced Therapy Medicinal Products market.

Key companies operating in the global Global Advanced Therapy Medicinal Products market include , Spark Therapeutics, Bluebird Bio, Novartis, UniQure, Celgene Corporation, Gilead Lifesciences, Kolon TissueGene, JCR Pharmaceuticals, MEDIPOST, Vericel Corporation, PHARMICELL

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1784327/global-advanced-therapy-medicinal-products-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Global Advanced Therapy Medicinal Products market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Global Advanced Therapy Medicinal Products Market Segment By Type:

, Cell Therapy, CAR-T Therapy, Gene Therapy, Tissue Engineered Product

Global Global Advanced Therapy Medicinal Products Market Segment By Application:

Advanced therapy medicinal products(ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. Market Analysis and Insights: Global Advanced Therapy Medicinal Products Market Prior to COVID-19, the market for Advanced Therapy Medicinal Products was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 20212026, whereas post-COVID-19 scenario, the market for Advanced Therapy Medicinal Products is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 20212026. The solicitation of proposals by the governments and publicprivate companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Advanced Therapy Medicinal Products market. Global Advanced Therapy Medicinal Products Scope and Segment The global Advanced Therapy Medicinal Products market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Advanced Therapy Medicinal Products market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Advanced Therapy Medicinal Products market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026. This report also analyzes the impact of Coronavirus COVID-19 on the Advanced Therapy Medicinal Products industry. By the type, the market is primarily split into Cell Therapy CAR-T Therapy Gene Therapy Tissue Engineered Product By the application, this report covers the following segments Hospital Clinic

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Global Advanced Therapy Medicinal Products market.

Key companies operating in the global Global Advanced Therapy Medicinal Products market include , Spark Therapeutics, Bluebird Bio, Novartis, UniQure, Celgene Corporation, Gilead Lifesciences, Kolon TissueGene, JCR Pharmaceuticals, MEDIPOST, Vericel Corporation, PHARMICELL

Key questions answered in the report:

For Discount, COVID-19 Impact Analysis, Customization in the Report: https://www.qyresearch.com/customize-request/form/1784327/global-advanced-therapy-medicinal-products-market

TOC

1 Market Overview of Advanced Therapy Medicinal Products1.1 Advanced Therapy Medicinal Products Market Overview1.1.1 Advanced Therapy Medicinal Products Product Scope1.1.2 Market Status and Outlook1.2 Global Advanced Therapy Medicinal Products Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Advanced Therapy Medicinal Products Market Size by Region (2015-2026)1.4 Global Advanced Therapy Medicinal Products Historic Market Size by Region (2015-2020)1.5 Global Advanced Therapy Medicinal Products Market Size Forecast by Region (2021-2026)1.6 Covid-19 Impact on Key Regions, Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.6.1 North America Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.6.2 Europe Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.6.3 China Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.6.5 Latin America Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Advanced Therapy Medicinal Products Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.7.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.7.2 Covid-19 Impact: Commodity Prices Indices1.7.3 Covid-19 Impact: Global Major Government Policy 2 Covid-19 Impact on Advanced Therapy Medicinal Products Market Overview by Type2.1 Global Advanced Therapy Medicinal Products Market Size by Type: 2015 VS 2020 VS 20262.2 Global Advanced Therapy Medicinal Products Historic Market Size by Type (2015-2020)2.3 Global Advanced Therapy Medicinal Products Forecasted Market Size by Type (2021-2026)2.4 Cell Therapy2.5 CAR-T Therapy2.6 Gene Therapy2.7 Tissue Engineered Product 3 Covid-19 Impact on Advanced Therapy Medicinal Products Market Overview by Application3.1 Global Advanced Therapy Medicinal Products Market Size by Application: 2015 VS 2020 VS 20263.2 Global Advanced Therapy Medicinal Products Historic Market Size by Application (2015-2020)3.3 Global Advanced Therapy Medicinal Products Forecasted Market Size by Application (2021-2026)3.4 Hospital3.5 Clinic 4 Covid-19 Impact on Global Advanced Therapy Medicinal Products Competition Analysis by Players4.1 Global Advanced Therapy Medicinal Products Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Advanced Therapy Medicinal Products as of 2019)4.3 Date of Key Manufacturers Enter into Advanced Therapy Medicinal Products Market4.4 Global Top Players Advanced Therapy Medicinal Products Headquarters and Area Served4.5 Key Players Advanced Therapy Medicinal Products Product Solution and Service4.6 Competitive Status4.6.1 Advanced Therapy Medicinal Products Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Spark Therapeutics5.1.1 Spark Therapeutics Profile5.1.2 Spark Therapeutics Main Business and Companys Total Revenue5.1.3 Spark Therapeutics Products, Services and Solutions5.1.4 Spark Therapeutics Revenue (US$ Million) (2015-2020)5.1.5 Spark Therapeutics Recent Development and Reaction to Covid-195.2 Bluebird Bio5.2.1 Bluebird Bio Profile5.2.2 Bluebird Bio Main Business and Companys Total Revenue5.2.3 Bluebird Bio Products, Services and Solutions5.2.4 Bluebird Bio Revenue (US$ Million) (2015-2020)5.2.5 Bluebird Bio Recent Development and Reaction to Covid-195.3 Novartis5.5.1 Novartis Profile5.3.2 Novartis Main Business and Companys Total Revenue5.3.3 Novartis Products, Services and Solutions5.3.4 Novartis Revenue (US$ Million) (2015-2020)5.3.5 UniQure Recent Development and Reaction to Covid-195.4 UniQure5.4.1 UniQure Profile5.4.2 UniQure Main Business and Companys Total Revenue5.4.3 UniQure Products, Services and Solutions5.4.4 UniQure Revenue (US$ Million) (2015-2020)5.4.5 UniQure Recent Development and Reaction to Covid-195.5 Celgene Corporation5.5.1 Celgene Corporation Profile5.5.2 Celgene Corporation Main Business and Companys Total Revenue5.5.3 Celgene Corporation Products, Services and Solutions5.5.4 Celgene Corporation Revenue (US$ Million) (2015-2020)5.5.5 Celgene Corporation Recent Development and Reaction to Covid-195.6 Gilead Lifesciences5.6.1 Gilead Lifesciences Profile5.6.2 Gilead Lifesciences Main Business and Companys Total Revenue5.6.3 Gilead Lifesciences Products, Services and Solutions5.6.4 Gilead Lifesciences Revenue (US$ Million) (2015-2020)5.6.5 Gilead Lifesciences Recent Development and Reaction to Covid-195.7 Kolon TissueGene5.7.1 Kolon TissueGene Profile5.7.2 Kolon TissueGene Main Business and Companys Total Revenue5.7.3 Kolon TissueGene Products, Services and Solutions5.7.4 Kolon TissueGene Revenue (US$ Million) (2015-2020)5.7.5 Kolon TissueGene Recent Development and Reaction to Covid-195.8 JCR Pharmaceuticals5.8.1 JCR Pharmaceuticals Profile5.8.2 JCR Pharmaceuticals Main Business and Companys Total Revenue5.8.3 JCR Pharmaceuticals Products, Services and Solutions5.8.4 JCR Pharmaceuticals Revenue (US$ Million) (2015-2020)5.8.5 JCR Pharmaceuticals Recent Development and Reaction to Covid-195.9 MEDIPOST5.9.1 MEDIPOST Profile5.9.2 MEDIPOST Main Business and Companys Total Revenue5.9.3 MEDIPOST Products, Services and Solutions5.9.4 MEDIPOST Revenue (US$ Million) (2015-2020)5.9.5 MEDIPOST Recent Development and Reaction to Covid-195.10 Vericel Corporation5.10.1 Vericel Corporation Profile5.10.2 Vericel Corporation Main Business and Companys Total Revenue5.10.3 Vericel Corporation Products, Services and Solutions5.10.4 Vericel Corporation Revenue (US$ Million) (2015-2020)5.10.5 Vericel Corporation Recent Development and Reaction to Covid-195.11 PHARMICELL5.11.1 PHARMICELL Profile5.11.2 PHARMICELL Main Business and Companys Total Revenue5.11.3 PHARMICELL Products, Services and Solutions5.11.4 PHARMICELL Revenue (US$ Million) (2015-2020)5.11.5 PHARMICELL Recent Development and Reaction to Covid-19 6 North America Advanced Therapy Medicinal Products by Players and by Application6.1 North America Advanced Therapy Medicinal Products Market Size and Market Share by Players (2015-2020)6.2 North America Advanced Therapy Medicinal Products Market Size by Application (2015-2020) 7 Europe Advanced Therapy Medicinal Products by Players and by Application7.1 Europe Advanced Therapy Medicinal Products Market Size and Market Share by Players (2015-2020)7.2 Europe Advanced Therapy Medicinal Products Market Size by Application (2015-2020) 8 China Advanced Therapy Medicinal Products by Players and by Application8.1 China Advanced Therapy Medicinal Products Market Size and Market Share by Players (2015-2020)8.2 China Advanced Therapy Medicinal Products Market Size by Application (2015-2020) 9 Rest of Asia Pacific Advanced Therapy Medicinal Products by Players and by Application9.1 Rest of Asia Pacific Advanced Therapy Medicinal Products Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Advanced Therapy Medicinal Products Market Size by Application (2015-2020) 10 Latin America Advanced Therapy Medicinal Products by Players and by Application10.1 Latin America Advanced Therapy Medicinal Products Market Size and Market Share by Players (2015-2020)10.2 Latin America Advanced Therapy Medicinal Products Market Size by Application (2015-2020) 11 Middle East & Africa Advanced Therapy Medicinal Products by Players and by Application11.1 Middle East & Africa Advanced Therapy Medicinal Products Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Advanced Therapy Medicinal Products Market Size by Application (2015-2020) 12 Advanced Therapy Medicinal Products Market Dynamics12.1 Covid-19 Impact: Industry Trends12.2 Covid-19 Impact: Market Drivers12.3 Covid-19 Impact: Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View post:
Global Advanced Therapy Medicinal Products Market Size, Analytical Overview, Growth Factors, Demand, Trends and Forecast to 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

DURANGO, Colo. After nearly a two-year wait, Colorado Parks and Wildlife hatchery staff and biologists in Durango have spawned a new lineage of Colorado River cutthroat trout that were rescued from a remote stream during the 416 Fire in 2018.

This marks a major milestone forCPWs on-going species conservation work in Colorado, and the result of decades of work by dedicated biologists, researchers and field staff.

Fertilized eggs of the San Juan cutthroats will hatch by mid-summer; some of the fingerlings will be placed in back-country streams in the southwest area of the state and others will be held at the Durango hatchery to start a sustainable brood stock. Now, the hatchery staff and biologists will continue the long-term effort to restore these native trout to their home waters.

Im thrilled that weve gotten a spawn from these fish, its been a long process and weve got a lot more work to do, said Jim White, aquatic biologist forCPWin Durango.

The story of these fish that hold a unique genetic marker goes back nearly 150 years and includes some serious biological detective work. Since the 1970s,CPWaquatic biologists have searched back-country streams looking for isolated populations of cutthroats Colorados native trout. In southwest Colorado in the 1980s and 1990s, biologists found cutthroat trout that were suspected to have unique characteristics in eight small streams. Back then, however, technology to analyze genetics fully was still being developed. The biologists kept their eyes on the fish and made sure non-native trout were not stocked nearby.

In 2012, researchers from the University of Colorado went to the Smithsonian National Museum of Natural History looking for preserved specimens of cutthroat trout that had been collected in Colorado. Two of the specimens they found were taken from the San Juan River near Pagosa Springs in 1874.

An analysis showed that the fish had genetic fingerprints specific to the San Juan River Basin.CPWresearchers then began a similar analysis of the cutthroats theyd found in southwest Colorado. By this time, genetic-analysis technology had advanced and in early 2018 scientists confirmed that the marker in the museum specimens matched the cutthroat trout recently found in the wild.

Biologists and hatchery staff then made a plan to start propagating the fish. The 416 Fire helped push the project along.

When the fire started north of Durango, biologists worried that ash and sediment run-off could kill the cutthroats in the remote streams. SoCPWworked with the San Juan National Forest to go into the area to capture the wild trout and bring them to a special isolation hatchery in Durango. Only 54 cutthroat were recovered from the fire area.

White and Durango Hatchery Manager Toby Mourning have been concerned because the fish did not produce any spawn last year and some of the fish died. But the turnaround this year is a major milestone for the restoration effort.

Were not getting a lot of eggs, but enough to provide some for a limited amount of stocking and some to start a captive population that will be sustainable, Mourning said.

In order to protect the fish,CPWis not providing details on stream locations. Biologists hope, however, that in a few years anglers will be able to find this unique cutthroat trout in the wild.

White explained that the work on this native is a significant conservation effort. In 2018, after the genetics of the fish were confirmed, he said: We always ask ourselves, What if we could go back to the days before mining, pioneer settlement and wide-spread non-native fish stocking to see what we had here? Careful work over the years by biologists, finding those old specimens in the museum and the genetic testing gave us the chance, essentially, to go back in time. Now we have the opportunity to bring this native trout back to southwest Colorado.

See original here:
Durango hatchery takes first spawn from rare cutthroat trout rescued in 416 Fire - Fort Morgan Times

Recommendation and review posted by Bethany Smith

The market research report published by QYResearch is a brilliant, in-dept, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Preimplantation Genetic Testing market. It informs readers about key trends and opportunities in the global Preimplantation Genetic Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Preimplantation Genetic Testing market.

Key companies operating in the global Preimplantation Genetic Testing market include Illumina, Thermo Fisher, Agilent Technologies, Perkinelmer, Coopersurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1781757/covid-19-impact-on-preimplantation-genetic-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Preimplantation Genetic Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Preimplantation Genetic Testing Market Segment By Type:

, Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis

Global Preimplantation Genetic Testing Market Segment By Application:

Maternity Centers & Fertility Clinics Hospitals, Diagnostic Labs, and Service Providers Research Laboratories & Academic Institutes

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Preimplantation Genetic Testing market.

Key companies operating in the global Preimplantation Genetic Testing market include Illumina, Thermo Fisher, Agilent Technologies, Perkinelmer, Coopersurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, etc.

Key questions answered in the report:

For Discount, COVID-19 Impact Analysis, Customization in the Report: https://www.qyresearch.com/customize-request/form/1781757/covid-19-impact-on-preimplantation-genetic-testing-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Preimplantation Genetic Testing Industry1.7 COVID-19 Impact: Preimplantation Genetic Testing Market Trends 2 Global Preimplantation Genetic Testing Quarterly Market Size Analysis2.1 Preimplantation Genetic Testing Business Impact Assessment COVID-192.1.1 Global Preimplantation Genetic Testing Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Preimplantation Genetic Testing Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global Preimplantation Genetic Testing Quarterly Market Size, 2019 VS 20203.2 By Players, Preimplantation Genetic Testing Headquarters and Area Served3.3 Date of Key Players Enter into Preimplantation Genetic Testing Market3.4 Key Players Preimplantation Genetic Testing Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Preimplantation Genetic Testing Segments, By Type4.1 Introduction1.4.1 Preimplantation Genetic Screening1.4.2 Preimplantation Genetic Diagnosis4.2 By Type, Global Preimplantation Genetic Testing Market Size, 2019-2021 5 Impact of Covid-19 on Preimplantation Genetic Testing Segments, By Application5.1 Overview5.5.1 Maternity Centers & Fertility Clinics5.5.2 Hospitals, Diagnostic Labs, and Service Providers5.5.3 Research Laboratories & Academic Institutes5.2 By Application, Global Preimplantation Genetic Testing Market Size, 2019-20215.2.1 By Application, Global Preimplantation Genetic Testing Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Illumina7.1.1 Illumina Business Overview7.1.2 Illumina Preimplantation Genetic Testing Quarterly Revenue, 20207.1.3 Illumina Preimplantation Genetic Testing Product Introduction7.1.4 Illumina Response to COVID-19 and Related Developments7.2 Thermo Fisher7.2.1 Thermo Fisher Business Overview7.2.2 Thermo Fisher Preimplantation Genetic Testing Quarterly Revenue, 20207.2.3 Thermo Fisher Preimplantation Genetic Testing Product Introduction7.2.4 Thermo Fisher Response to COVID-19 and Related Developments7.3 Agilent Technologies7.3.1 Agilent Technologies Business Overview7.3.2 Agilent Technologies Preimplantation Genetic Testing Quarterly Revenue, 20207.3.3 Agilent Technologies Preimplantation Genetic Testing Product Introduction7.3.4 Agilent Technologies Response to COVID-19 and Related Developments7.4 Perkinelmer7.4.1 Perkinelmer Business Overview7.4.2 Perkinelmer Preimplantation Genetic Testing Quarterly Revenue, 20207.4.3 Perkinelmer Preimplantation Genetic Testing Product Introduction7.4.4 Perkinelmer Response to COVID-19 and Related Developments7.5 Coopersurgical7.5.1 Coopersurgical Business Overview7.5.2 Coopersurgical Preimplantation Genetic Testing Quarterly Revenue, 20207.5.3 Coopersurgical Preimplantation Genetic Testing Product Introduction7.5.4 Coopersurgical Response to COVID-19 and Related Developments7.6 Abbott Laboratories7.6.1 Abbott Laboratories Business Overview7.6.2 Abbott Laboratories Preimplantation Genetic Testing Quarterly Revenue, 20207.6.3 Abbott Laboratories Preimplantation Genetic Testing Product Introduction7.6.4 Abbott Laboratories Response to COVID-19 and Related Developments7.7 Natera7.7.1 Natera Business Overview7.7.2 Natera Preimplantation Genetic Testing Quarterly Revenue, 20207.7.3 Natera Preimplantation Genetic Testing Product Introduction7.7.4 Natera Response to COVID-19 and Related Developments7.8 Rubicon Genomics7.8.1 Rubicon Genomics Business Overview7.8.2 Rubicon Genomics Preimplantation Genetic Testing Quarterly Revenue, 20207.8.3 Rubicon Genomics Preimplantation Genetic Testing Product Introduction7.8.4 Rubicon Genomics Response to COVID-19 and Related Developments7.9 Oxford Gene Technology7.9.1 Oxford Gene Technology Business Overview7.9.2 Oxford Gene Technology Preimplantation Genetic Testing Quarterly Revenue, 20207.9.3 Oxford Gene Technology Preimplantation Genetic Testing Product Introduction7.9.4 Oxford Gene Technology Response to COVID-19 and Related Developments7.10 Yikon Genomics7.10.1 Yikon Genomics Business Overview7.10.2 Yikon Genomics Preimplantation Genetic Testing Quarterly Revenue, 20207.10.3 Yikon Genomics Preimplantation Genetic Testing Product Introduction7.10.4 Yikon Genomics Response to COVID-19 and Related Developments7.11 Scigene7.11.1 Scigene Business Overview7.11.2 Scigene Preimplantation Genetic Testing Quarterly Revenue, 20207.11.3 Scigene Preimplantation Genetic Testing Product Introduction7.11.4 Scigene Response to COVID-19 and Related Developments7.12 Beijing Genomics Institute7.12.1 Beijing Genomics Institute Business Overview7.12.2 Beijing Genomics Institute Preimplantation Genetic Testing Quarterly Revenue, 20207.12.3 Beijing Genomics Institute Preimplantation Genetic Testing Product Introduction7.12.4 Beijing Genomics Institute Response to COVID-19 and Related Developments7.13 Good Start Genetics7.13.1 Good Start Genetics Business Overview7.13.2 Good Start Genetics Preimplantation Genetic Testing Quarterly Revenue, 20207.13.3 Good Start Genetics Preimplantation Genetic Testing Product Introduction7.13.4 Good Start Genetics Response to COVID-19 and Related Developments7.14 Invicta Genetics7.14.1 Invicta Genetics Business Overview7.14.2 Invicta Genetics Preimplantation Genetic Testing Quarterly Revenue, 20207.14.3 Invicta Genetics Preimplantation Genetic Testing Product Introduction7.14.4 Invicta Genetics Response to COVID-19 and Related Developments7.15 Combimatrix7.15.1 Combimatrix Business Overview7.15.2 Combimatrix Preimplantation Genetic Testing Quarterly Revenue, 20207.15.3 Combimatrix Preimplantation Genetic Testing Product Introduction7.15.4 Combimatrix Response to COVID-19 and Related Developments7.16 Genea Limited7.16.1 Genea Limited Business Overview7.16.2 Genea Limited Preimplantation Genetic Testing Quarterly Revenue, 20207.16.3 Genea Limited Preimplantation Genetic Testing Product Introduction7.16.4 Genea Limited Response to COVID-19 and Related Developments7.17 Progenesis7.17.1 Progenesis Business Overview7.17.2 Progenesis Preimplantation Genetic Testing Quarterly Revenue, 20207.17.3 Progenesis Preimplantation Genetic Testing Product Introduction7.17.4 Progenesis Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See more here:
Preimplantation Genetic Testing Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Bulletin Line

Recommendation and review posted by Bethany Smith

My wife and I can both roll our tongues but our son can't. I'm worried about his paternity (Photo: Shutterstock)

I am a 36-year-old woman and have no children, but I am planning on having some in a few years. Is it true that with advancing age I increase my chances of getting a child with Downs syndrome or cerebral palsy?

ALSO READ: Ask the doctor: Is penile enlargement surgery considered plastic surgery? Does it work?

Yes, these conditions have been associated with problematic pregnancies and abnormal foetal development. After age 35, older eggs tend to have abnormal cell division where the chromosomes may fail to separate in the correct way, leading to an excess number of expected chromosomes.

For example, in Downs syndrome, the foetus has an extra chromosome resulting in what is referred to as trisomy. Cerebral palsy is associated with complications of advanced parental age, especially the mothers. These may include miscarriages, multiple births, high blood pressure, gestational diabetes, and genetic mutations that impact brain development. Studies have also suggested that an older couple is more likely to use infertility procedures that can increase the risk of multiples and other risk factors.

I discovered that my fiances sister has albinism. How likely is it that any of our future children develops the condition?

There is a 50 percent chance your fiance is a carrier for the albinism gene. If this holds true, then there is a 25 percent chance that your future children may develop this condition.

My wife can roll her tongue (the rolling tongue gene). So can I. But our son, now 4, cant. I am worried about my childs paternity but dont want to stir the marriage yet. Do you think I should be worried or is there a genetic explanation?

There should be no cause to worry. More recent studies disputed the misleading assumption that leads to the conclusion that is worrying you. There was a study on identical twins who differed in their tongue-rolling trait, suggesting that the trait was not entirely under genomic influence as identical twins have the same genetic makeup.

I hope to get a child through a sperm bank. Do you think my request for physical characteristics of the sperm donor will help towards getting desirable traits in my future child?

ALSO READ: Why its better to have children before your 40s

Yes, most physical characteristics are easily inherited from parents to their offspring. However, this could be a mixture of traits from both the donor and the recipient.

How far is the world from genetically engineering desirable traits into people and consequently having designer babies?

It is already happening on a smaller scale for certain traits, for example women or men going to sperm banks look for super straights in their donors for IVF procedures.

The world is also moving towards precision medicine, or what is commonly known as personalised medicine where everyone has their medicine tailor-made to suit their genes and condition based on their genetic fingerprint.

With technologies such as CRISPR/Cas9 gene editing, the future of designer babies is possible although ethical considerations in human cloning restrict such practices and may fail to promote advancements in these technologies.

Can I influence my childrens personalities or are they predetermined before birth?

To some extent yes, but personality is influenced by various factors. One component may come from the genes and the other from environmental interactions. For example, exposure to different life circumstances greatly influences ones personality.

ALSO READ: Ask the doctor: How do I bring back the white colour of my child's discoloured teeth?

My four-year-old twins are very different. My son has a real mean streak. Hes always been like that. His sister is kind. I have been responsible for their upbringing so far. Are character traits in the genes?

The difference could be in their genetic makeup. As we know, we inherit half of our genes from each parent and different personality traits could arise from this. In addition, the contrast in their personality could emanate from their daily interactions with the external world, such as from observations.

For More of This Stories Subscribe to the Standard Epaper to get a copy of Eve Woman in the Standard

You also have not told us if you treat the children differently whereby in most cases girls are treated kindly with lots of pampering, which is thus reflected in their behaviour. Boys who are often groomed to harden up to face the real world like men and turn out as brave warriors.

As a geneticist, do you think psychopaths are born or made?

I think it is a mixed bag of fortunes here. Psychopaths could result from nature and nurture. Several studies have pointed to the existence of genetic abnormalities in psychopaths, whereas other cases have risen purely from their upbringing. For example, we have had cases of sociopathic behaviour arising after traumatic experiences and drug addiction.Couples can undergo genetic testing to determine if they have any conditions their children can inherit (Photo: Shutterstock)

I have read a bit about genetic testing for couples, and I am considering it before we start a family. My question is, if they find something worrying (my sister died of sickle cell anaemia) can it be prevented because we know beforehand?

It may not be prevented in its entirety, but may help in early management of the outcome. It may also help in decision making whether to proceed and have children in the full knowledge that they may develop an inherited condition from parents. For your case, you could be a carrier for sickle cell disease and this prepares you to seek genetic therapy such as stem cell transplants to correct the abnormal red (sickle) cells.

I did the BRCA gene test and I have the mutated gene. What are the chances I could get ovarian or breast cancer?

A mutated BRCA gene is only an indicator of higher risk of developing either ovarian or breast cancer. It does not mean that you already have the cancer. It helps you prepare to seek and make a plan for testing and monitoring of signs of the development of these cancers so that preventative or management measures can be instituted. This may help in following a lifestyle that can reduce the chances of accelerating the development of the disease.

Is there a genetic explanation as to why children, especially firstborns, look like their fathers?

Well, it is not always the case. Physical characteristics of the offspring sometimes might be a mixture of both the mothers and fathers characteristics. There are, however, extremes where a child may look like a copy of either parent. A child is a result of the union of genes of a mother and father, and the strength of expression of these genes may differ.

There is conflicting information out there about genetically modified foods. What are the facts and fiction on this?

Genetically modified foods refer to food items whose source material production, be it plant or animal, involves intentional mixing (manipulation) of genetic material not naturally found in the pure/natural breed.

The fuss brought about by anti-GMO campaigners has been related, in my opinion, to a lack of information. The genes being included have their function known from a science point of view. However, genes may interact and the results may not be known fully. How a gene will behave in the new organism is assumed to be what is known, but it does not rule out undesired effects. However, before a gene is used in GMO, experimental tests are usually performed to understand different scenarios under which it may elicit undesired effects.

Dr Fredrick Nindo, a geneticist, is a visiting post-doctoral research fellow at the Mediterranean Infection Institute for Research in Cancer and Ageing, France.

?

Do not miss out on the latest news. Join the Eve Digital Telegram channel HERE.

Visit link:
Ask the doctor: Is there a chance I am not my sons father? - The Standard

Recommendation and review posted by Bethany Smith

Breast Cancer Predictive Genetic Testing Market 2020, by Tools, Services, Business Application, Company Profiles, Trends, Demand and Investment Opportunities to 2026

A comprehensive and elaborate primary analysis on GlobalBreast Cancer Predictive Genetic TestingMarket report highlights numerous facts such as development factors, business enhancement strategies, statistical growth, financial status to help readers and clients to understand the market on a global scale. The market has uncovered rapid development in the current and past years and is going to progress with continuing development in the upcoming years. Overall, the study offers an in-depth overview of the worldwide market covering all major parameters. The study offers important statistics on the market status of producers and offers useful advice and direction for businesses and individuals interested in the industry. The research was provided for leading growth status, including developments, segmentation, landscape analysis, product types and applications. The industry report focuses on the growth opportunities, which will help the Global Breast Cancer Predictive Genetic Testing market to expand operations in the existing markets. The current Large Screen Splicing System market research report has demonstrated all the vital market growth factors and economic fluctuations mentioned owing to the immense attention gained in recent years.

Request for Sample Report @https://www.indexmarketsresearch.com/report/global-and-china-breast-cancer-predictive-genetic-testing-market/302630/#requestforsample

The report thoroughly describes and maps the Breast Cancer Predictive Genetic Testing Market with a flawless discernment on the existing situation of competition in the market. This will ultimately be helping investors as well as manufacturers if the industry, in better understanding the current and future directions, the Breast Cancer Predictive Genetic Testing Market will be headed in. This report also presents product specification, manufacturing process, and product cost structure, etc. Production is separated by regions, technology, and applications. Other important aspects that have been meticulously studied in the Breast Cancer Predictive Genetic Testing market report is Demand and supply dynamics, import and export scenario, industry processes and cost structures and major R&D initiatives. In the end, the report includes Breast Cancer Predictive Genetic Testing new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. In addition, the global Breast Cancer Predictive Genetic Testing market report delivers concise information about the federal regulations and policies that may indirectly affect market growth as well as the financial state. Further, the researchers have done the industry analysis to see the impact of numerous factors and understand the whole attractiveness of the industry. The market review helps to summaries the industrial and financial development within the industry through expert analysis. Later on, the report analyzes gross sales (volume & value), market share, market growth rate, market size on the basis of a variety of applications.

With the tables and figures, the Breast Cancer Predictive Genetic Testing market report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. The information available in the global Breast Cancer Predictive Genetic Testing market report is not only based on the facts but also on the case studies, which analysts have included to deliver appropriate information to the clients in a well-versed manner. The report also covers in-depth description, competitive scenario, wide product portfolio of prime players active in this market and business strategies adopted by competitors along with their SWOT analysis. The report also provides Porter analysis, PESTEL analysis and market attractiveness which helps to better understand the market scenario(macro and micro level). Some of these influences include annual revenue, key segments, production capacity and new products. Industry principles are also documented for market analysis. This is coupled with understanding business practices of the market, sympathetic governments presence in the industry, classifying leverage of Global Breast Cancer Predictive Genetic Testing market globally, reviewing commercial terms and conditions and analyzing market subjects and trends. The situation of the global market at the global and regional level is also described in the global Breast Cancer Predictive Genetic Testing market report through geographical segmentation.

Areas to be closely scrutinized for a clear understanding of the Breast Cancer Predictive Genetic Testing market inNorth America, Central and South America, Asia Pacific, Africa, Europe, India and others.This informative report involved some top-level manufacturers profiling. In this report, a comprehensive inquiry into the market has been completed. It consists of exams conducted on previous innovations, ongoing market conditions and future outlook.

Global Breast Cancer Predictive Genetic Testing Market Leading Players:Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Global Breast Cancer Predictive Genetic Testing Market Product Type:High Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes

Global Breast Cancer Predictive Genetic Testing Market Application Segment:Hospitals, Clinics, Others

Breast Cancer Predictive Genetic Testing Market Report Highlights The report provides a detailed analysis on current and future market trends to identify the investment opportunities Market forecasts till 2026, using estimated market values as the base numbers Key market trends across the business segments, Regions and Countries Key developments and strategies observed in the market Market Dynamics such as Drivers, Restraints, Opportunities and other trends In-depth company profiles of key players and upcoming prominent players Growth prospects among the emerging nations through 2026 Market opportunities and recommendations for new investments

This report provides pin-point analysis of Global Breast Cancer Predictive Genetic Testing Market:1. The report provides a forward-looking perspective on the global Breast Cancer Predictive Genetic Testing market historical data, status, and future forecast, production, revenue, consumption.2. It helps to identify rising trends, drivers, growth influencing factors in global Breast Cancer Predictive Genetic Testing market and regions.3. It provides full insights of market and in-depth analysis of market segments(by manufacturers, regions, types, and applications) to easily make business decisions.4. The report provides a 10-year forecast assessment of how the market is expected to grow in the future based on current and future market potential and advantages, opportunities and challenges.5. It helps to plan Business Strategies by understanding the rising trends shaping and enhancing Breast Cancer Predictive Genetic Testing market development.6. It helps to understand competitive developments such as expansions, acquisitions, agreements, and new product launches in the Breast Cancer Predictive Genetic Testing market.

Read Detailed Index Report @https://www.indexmarketsresearch.com/report/global-and-china-breast-cancer-predictive-genetic-testing-market/302630/

Analytical Tools:

The report offers exactly studied and analyzed data of the key industry players along with their share in the market. The analytical tools used during the research includes Porters five forces analysis, SWOT analysis, and investment feasibility and returns analysis. These vital tools are used to analyze the growth of the top vendors in the market.

Additionally, the Global Breast Cancer Predictive Genetic Testing Market report comprises the in-depth study of the market segmentation such as types and applications. However, sub-segments studying in this report are crucial for knowing the preference of the shifting market demands. Likewise, the research Global Breast Cancer Predictive Genetic Testing Market report provides the deep study of the sales medium channels, traders, dealers, distributors at global as well as local level. Moreover, the Global Breast Cancer Predictive Genetic Testing Market report

Finally, Overall data will help clients to make critical tactical business decisions as well as business planning and to know the scope of future developments. This report provides a competitive study, demand-side statistics for which we interview end-users and organize procedure surveys with the help of secondary research techniques, Breast Cancer Predictive Genetic Testing company reports, regulatory information, analytical techniques, Breast Cancer Predictive Genetic Testing production sales volume and expenditure statistics.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Request customize:-If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

Contact Us @sales@indexmarketsresearch.com

Read more from the original source:
Global Breast Cancer Predictive Genetic Testing Industry Developments & Assessment 2020-2026 : Roche,... - Azizsalon News

Recommendation and review posted by Bethany Smith

A new study has suggested that genetics could be the reason as to why some women gain weight while they're on birth control.

Many women take birth controlregularlyin order to regulate their menstrual cycle and prevent pregnancy. But like with any medication, it comes with its fair share of side effects. Some of them can be a mere nuisance whereas others can be serious or even life-threatening.

One side effect that leans towards the former is weight gain. While it can happen, it doesn't happen to every woman who goes on birth control. That can be frustrating if this side effect has happened to you. But now,a new study has revealed that genetics could determine why some women gain weight while using birth control.

The study in question was carried out by researchers at the University of Colorado Anschutz Medical Campus. They recruited 276 women to see if they gained weight while having an etonogestrel contraceptive implant inserted in their arm. Since it contains etonogestrel, it inhibits ovulation. Moreover, it's arguably the most effective method of birth control.

Related: The Strangest Myths About Birth Control Debunked

The study found that 73.9 percent of participants gained weight with theetonogestrel contraceptive implant. When they looked at just how much weight they gained, the median was 3.2 kilograms, which is just over seven pounds. That median was determined over a time span of 27 months.

After that, researchers looked into whether or not genetics played a role in why some participants gained weight, and others didn't. That study found genetic variants in estrogen receptor 1 (ESR1) were associated with weight gain. Women with two copies of ESR1 were found to have gained an average of 14.1 kilograms (over 31 pounds) while using the aforementionedcontraceptive implant.

There are currently no links found between ESR1 and obesity. However, past research had found links between ESR1 and how it affects other medications. Also, it's not yet known if ESR1 is only linked to weight gain to other forms of birth control outside the contraceptive implant used in the study. More studies will need to be conducted in order to determine this. That being said, this is a great start looking into this particular matter.

"For years, women have said that birth control causes them to gain weight but many doctors failed to take them seriously.Now we have looked at the genetics and found that the way genes interact with some hormones in birth control could help explain why some women gain more weight than others," explained Aaron Lazorwitz, Md., the study's lead author.

Next: Hailey Bieber Admits That Starting Birth Control Lead To Acne Breakouts

Source:TheJakarataPost

How To Effectively Quit Smoking While Trying To Conceive

Elizabeth Sarah Larkin is a full-time freelancer who specializes in writing, social media, and public relations. She has published articles for many online publications, including Babygaga and Moms.com. She graduated from Conestoga College with a Bachelor of Public Relations (Honours), where she learned and honed her skills. Her interests include music, video games and working out. You can follow her on Twitter (@ElizabethSL95) or Instagram (@elizabethsarahl); or you can contact her at elizabeth@elizabethsarahlarkin.ca

Original post:
Study Suggests That Genetics Could Be Why Some Women Gain ...

Recommendation and review posted by Bethany Smith

May 19 (UPI) -- African-American and white women share several genetic mutations that increase risk for breast cancer, according to a study published Tuesday by the Journal of the National Cancer Institute.

Researchers at Boston University and the Mayo Clinic found that mutations of the BRCA1, BRCA2 and PALB2 genes, which are known to raise breast cancer risk in white women, including those of Ashkenazi Jewish descent, are also found in African-American women with the disease.

The genetic mutations have been associated with a more than seven-fold higher risk of breast cancer, the researchers noted.

"We also found that mutations in PALB2, RAD51C and RAD51D confer increased risks of estrogen receptor negative breast cancer in the African-American population," study co-author Fergus Couch, the Zbigniew and Anna M. Scheller Professor of Medical Research at the Mayo Clinic, said in a statement.

About one out of every eight women in the United States will develop invasive breast cancer during their lifetimes, according to BreastCancer.org. African-American women tend to be diagnosed at a younger age and are more likely to die from the disease.

However, rates of breast cancer genetic testing are substantially lower in African-American women than in white women, the authors of the JNCI study said. Differences in health recommendations given to African-American women have been identified as one of the drivers of this disparity, they added.

For the study, Couch and his colleagues sequenced germline DNA from 5,054 African-American women with breast cancer and 4,993 age-matched African-American women without cancer, looking for mutations in 23 genes believed to predispose women to the disease. The researchers then estimated the risk of developing breast cancer associated with having a mutation in any of the genes.

They found that more than 7 percent of women with breast cancer, regardless of race, had a mutation in one of the genes, as compared with 2 percent of the controls. Among women with breast cancers that lacked estrogen receptors -- or had estrogen receptor negative breast cancer -- more than 10 percent had a mutation in one of these genes.

In comparison, 5 percent of women with estrogen receptor positive breast cancer had a mutation in the cancer-related genes.

In addition to common mutations of the BRCA1, BRCA2, PALB2, RAD51C and RAD51D, the authors identified four other genetic mutations associated with a more moderate increase in risk for breast cancer among the women in the study. Previous studies of women of African ancestry were too small to identify genetic mutations other than those affecting BRCA1 and BRCA2.

Based on these findings, testing for breast cancer predisposition genes can prevent breast cancer deaths -- both in women who have never had breast cancer and in women with breast cancer -- according to the researchers.

"The multi-gene panels that are currently available to test women diagnosed with breast cancer or women at high risk due to their family history will be useful for African American women," said co-author Julie Palmer, director of Boston University's Slone Epidemiology Center.

"Depending on results of the testing and an individual's own weighing of pros and cons, a woman with a mutation in any of these genes may choose more aggressive screening for cancer, and women with mutations in the high risk BRCA1 and BRCA2 genes may choose removal of her breasts and/or ovaries as a way to prevent initial breast cancer or recurrence," she added.

Read the original here:
African-American, white women share genetic mutations ...

Recommendation and review posted by Bethany Smith

The global analytical report titled Genetic Testing market has been recently published by Market Research Inc to its expansive repository which helps to make informed decisions for business clients. The study includes a comprehensive analysis of this research report further also draws attention to historical records, existing market scenario and to future predictions of market growth.

Global competitors such as Genetic Testing are also highlighted in the study in order to get a stronger and effective outlook of the competition at domestic as well as global regions. The report further also offers comprehensive information based on primary and secondary research techniques to examine the data accurately

Request A sample copy of this Genetic Testing Market report at

https://www.marketresearchinc.com/request-sample.php?id=16612

The competitive landscape has been elaborated by profiling the leading key players

Abbott Laboratories, Bio-Rad Laboratories, Inc

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Genetic Testing Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

The geographical segmentation includes study of global regions such as North America, Latin America, Asia-Pacific, Africa, and Europe. The report also draws attention to recent advancements in technologies and certain methodologies which further help to boost the outcome of the businesses. Furthermore, it also offers a comprehensive data of cost structure such as the cost of manpower, tools, technologies, and cost of raw material. The report is an expansive source of analytical information of different business verticals such as type, size, applications, and end-users.

Grab Your Report at an Impressive Discount

https://www.marketresearchinc.com/ask-for-discount.php?id=16612

Objectives of global Genetic TestingMarket:

The report also includes information on significant market players in order to deliver penetrative insights into the businesses with regards to successful strategies of top-notch companies. Moreover, the report offers comprehensive information of several traders by presenting accurate facts and figures of market shares.

It concludes by throwing light on the recent developments that took place in the Genetic Testing market and their influence on the future growth of this market.

Inquire more or share questions if any before the purchase on this report at

https://www.marketresearchinc.com/enquiry-before-buying.php?id=16612

About Us

Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact:

Market Research Inc

Kevin

51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us: +1 (628) 225-1818

Write Us@sales@marketresearchinc.com

Here is the original post:
Genetic Testing Market Is Booming Across the Globe Explored in Latest Research with Top Key PlayersAbbott Laboratories, Bio-Rad Laboratories, Inc -...

Recommendation and review posted by Bethany Smith

BILLINGS Before the COVID-19 pandemic, way back in the 1300s there was a pestilence known as the Black Death, also called bubonic plague.

Estimated to have killed millions during several outbreaks, the bubonic plague is caused by a bacteria known as Yersinia pestis.

Although the new coronavirus pandemic has captured headlines and attention around the world over the past two months, bubonic plague has again reared its head, this time in the Greater Yellowstone Ecosystem. Recently published research by Mark Elbrock and his associates showed 47% of the 17 cougars that were captured and had their blood drawn in the southern GYE tested positive for exposure to the plague.

This suggests that: (1) Y. pestis may be present at higher levels in the GYE than previously assumed, Elbrock wrote in the Cambridge University Press, noting that the disease was also found in four of 11 mountain lions that were necropsied. His co-authors were Winston Vickers and Howard Quigley.

The study is not the first time that exposure to Y. pestis has been found in Greater Yellowstone Ecosystem cougars. In 2006, a study co-authored by Roman Biek and Toni Ruth, along with others, tested blood from 150 cougars collected over 15 years and found relatively low exposure to the bacteria less than 20%.

Ruth also found Yellowstone cougars in 2004 and 2005 that had succumbed to bubonic plague. When captured in the winter, they were infested with fleas. The animals died in the following summer.

Its a relatively common bacteria found in wildlife, more so in southern drier areas, said Dan Stahler, leader of the Yellowstone National Park Cougar Project.

The bacteria is commonly transmitted by fleas that infest rodents, everything from mice to ground squirrels. The cougars, along with other predators like coyotes, are exposed to the virus when they catch and eat infected animals.

Felines, including bobcats and lynxsee, tend to be more susceptible to Y. pestis than canines, Stahler said. For some reason, bears appear impervious to such infections, he added.

Being aware of contagions is why Stahler and his team approach any dead animal cautiously while conducting wildlife research.

Anyone in contact with animals needs to have such diseases at the forefront of their mind, he said.

Not to be fearful, or to panic, but its important to screen for it and be careful of it, he said.

In humans, bubonic plague causes enlarged lymph nodes in the armpits, groin and neck. It can also be accompanied by fever and muscle aches, along with other flu-like symptoms. Unlike COVID-19, it cant be transmitted from an infected person to others via respiratory droplets. Bubonic plague is also easily treated with a vaccine if caught soon enough.

According to Montana Fish, Wildlife and Parks website, detailed data on the distribution of plague in wildlife in Montana is not available, although it is believed to be present throughout the state. The most recent human case of plague in Montana was in 1992 when a hunter contracted the disease from a bobcat. In 1987, a hunter was infected after skinning an infected antelope.

Across the United States, only about seven people a year are infected, according to the Centers for Disease Control and Prevention. More prevalent in the Southwest, the United States saw spikes in human infections in 2006 and 2015, according to the CDC.

Prairie dogs are another species that is often infected by bubonic plague. In trying to reintroduce black-footed ferrets across the West, outbreaks of plague have repeatedly frustrated scientists efforts. Prairie dogs are the main food source for the ferrets, which also use the rodents dens as their living quarters.

The incidence of plague seems to increase in years with cooler summers that follow wet winters, Stahler said, possibly because those conditions are more conducive to flea survival.

Yellowstone National Parks cougar study continued this winter with the capture of seven cougars. Eight of the big cats are wearing GPS collars, allowing researchers to track their movements.

Soon-to-be published research based on a graduate students work on noninvasive genetic testing, like hair samples, is being used to provide insight to the parks cougar population. Stahler said the work shows that in the Northern Range of the park, which includes the Lamar Valley, there are about 35 to 45 cougars, a robust population.

The research team also continues to collect data via remote camera traps, which also will help with population estimates of the secretive animals. At one elk calf carcass, five lions were photographed feeding over several days.

We had one cool trigger where a mule deer went racing by and was then followed by a cougar, Stahler said.

Another series showed a whitetail deer racing past a camera near Hellroaring Creek, soon followed by a wolf. The wolf later walked back past the camera.

Unfortunately, the parks winter predator study was cut short in mid-March due to the coronavirus pandemic, Stahler said. Yellowstone National Park was closed to the public on March 23.

We decided to get our people home safely, he said.

View original post here:
Tale of bubonic plague in pumas revived by southern Yellowstone study - Sports and Weather Right Now

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hereditary Testing market.

Trusted Business Insights presents an updated and Latest Study on Hereditary Testing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hereditary Testing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hereditary Testing Market

The global hereditary testing market size was valued at USD 5.8 billion in 2019 and is projected to register at a CAGR of 6.3% during the forecast period. The expanding reproductive genetic health space is one of the key market drivers. Key players, such as Natera, have reported a continuous increase in test volumes in womens health genetic testing for inherited conditions. This reflects the growing acceptance of hereditary tests among the population, thereby accelerating the revenue growth.Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. For instance, in November 2019, the Division of Consolidated Laboratory Services (DCLS) of the Virginia Department of General Services screened 7,868 newborns for nearly 31 hereditary and metabolic disorders. Increasing penetration of newborn screening across the globe is further aiding in the revenue growth.

Reforms in genetic testing guidelines have led to inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offers information on some of the cancer risk factors and management recommendations for single and multiple gene panels.Gradual developments in the distribution model is likely to benefit the genetic testing market. Technology providers are playing a crucial role in the market growth by improving their distribution service and increasing the efficiency of technology. Companies are using a cloud-based distribution model to make bioinformatics technology available for use by other laboratories. As of March, 2019, around 14 licensees were using Constellation software commercially for the marketing of Non-invasive Prenatal Testing (NIPT) products.Although these hereditary tests have huge advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.DiseaseType Insights of Hereditary Testing Market

Product and service offerings with regard to various hereditary cancer testing continue to expand. Entry of major players, such as Quest, in this segment in the recent past, has significantly driven the hereditary testing market. Considering breast cancer genetic testing as a lucrative source of revenue, companies are focusing on business strategies to enhance their presence in this segment.One of the strategies is offering hereditary tests at a price lower than that offered by competitors. For instance, Color Genomics began selling its product for USD 259, whereas similar products offered by Myriad cost around USD 4,000. The increasing affordability of the tests is one of the key drivers of this segment. Furthermore, BRCA1 carriers have an 80% risk of developing breast cancer, which has also accelerated the developments in hereditary cancer testing market.

On the other hand, lung cancer is one of the major cancer forms that has a relatively few number of products. This is because most cases of lung cancer are not related to inherited genetic mutations. Similarly, for cervical cancer, most of the cases are caused by Human Papilloma Virus (HPV) and not genetic mutations. Lack of effective evidence over heritability of cervical cancer are driving the research activities in this market.Prenatal testing, irrespective of the associated risks, is increasingly gaining popularity. The cell-free DNA (cfDNA)-based NIPT testing is considered medically necessary by Anthem Blue Cross and Blue Shield of California. Previously, these players promoted cfDNA-based NIPT testing for trisomys 21, 18, and 13 only in high-risk pregnancies, as determined by maternal age and other factors.

Regional Insights of Hereditary Testing Market

Variations in regulatory frameworks pertaining to genetic tests across the world have significantly impacted the approval and commercialization of tests in the global market. Currently, a wide variety of genetic tests are being provided by several key companies in U.S. as well as several countries in Europe, Asia Pacific, and other regions.Europe accounted for the largest share in terms of revenue in 2019 and is likely to continue its dominance during the forecast period. This can be attributed to presence of key players providing genetic tests, high adoption of advanced treatments, and recommendations provided by government agencies to ensure the quality of hereditary testing services.In September 2019, Blueprint Genetics, a Finnish company, partnered with ARCHIMEDlife, a rare disease diagnostics company, to provide biochemical testing for rare diseases in North America. Through this partnership, both firms planned to diversify their range of genetic disease testing services to serve the customers better. Such initiatives are expected to strengthen the genetic testing scenario for hereditary disorders in North America, thereby accelerating regional revenue generation.

Market Share Insights of Hereditary Testing Market

Understanding the role of genetic mutation in disease occurrence has significantly accelerated the R&D in this market. Various retrospective studies are being carried out to understand the role of inherited mutations in disease pathology, which has led to key diagnostic developers, such as Quest Diagnostics, enter the market. Continuous authorizations and approvals of genetic tests by the government is expected to propel the organic revenue growth of operating companies.Some of the key players engaged in offering services and products in this market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Agilent Technologies, Inc.; Thermo Fisher Scientific, Inc.; Twist Bioscience; Sophia Genetics; Fulgent Genetic, Inc.; Medgenome; and CENTOGENE N.V.Furthermore, the expanding product portfolio is indicative of growing competition in the market. Each company is making focused efforts to offer products with competitive advantage. For example, cross-selling efforts by Natera helped the company witness lucrative revenue generation over the past years. The company promotes collective use of Horizon and Panorama products for women who have not undergone carrier screening tests in their first trimester.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hereditary Testing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global hereditary testing market report on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2019 2030)

Hereditary Cancer Testing

Lung Cancer

Breast Cancer

Colorectal Cancer

Cervical Cancer

Ovarian Cancer

Prostate Cancer

Stomach/Gastric Cancer

Melanoma

Sarcoma

Uterine Cancer

Pancreatic Cancer

Others

Hereditary Non-cancer Testing

Genetic Tests

Cardiac Diseases

Rare Diseases

Other Diseases

Newborn Genetic Screening

Preimplantation Genetic Diagnosis & Screening

Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests

Quick Read Table of Contents of this Report @ Hereditary Testing Market Size, Market Research and Industry Forecast Report, 2020-2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read this article:
Hereditary Testing Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith